Monograph Details
|
|
Ob/Gyn
> Menopause and HRT
|
|
FEMRING |
| Manufacturer |
|
Warner Chilcott Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Estradiol acetate 0.05mg/day, 0.1mg/day; vaginal ring. |
| Indications |
|
Moderate to severe vasomotor symptoms of menopause. Vulvar or vaginal atrophy (consider alternative treatments). |
| Children |
|
Not applicable. |
| Adults |
|
Insert 1 ring vaginally once every 3 months; replace. Use 0.05mg/day ring initially; may increase to 0.1mg/day ring if needed. |
| Contraindications |
|
Undiagnosed abnormal genital bleeding. Thrombophlebitis. Thromboembolic disorders. Breast or estrogen-dependent carcinoma. Pregnancy (Cat.X). |
| Precautions |
|
Reevaluate periodically; limit use to shortest duration consistent with treatment goals and risks. Women with a predisposition to vaginal irritation, ulceration, or ring expulsion (eg, vaginal stenosis, cervical prolapse, rectoceles, cystoceles). May use ring while treating vaginal infections. Patients with an intact uterus should almost always receive a progestin to avoid endometrial hyperplasia. Hepatic insufficiency. Conditions aggravated by fluid retention. Gallbladder disease. Metabolic bone disease associated with hypercalcemia. Do initial complete physical and repeat annually (include Pap smear, mammogram, and BP). Discontinue if cardiovascular disease or jaundice occurs, and at least 2 weeks before surgery associated with increased risk of thromboembolism. Nursing mothers. |
| Adverse Reactions |
|
See literature. Breakthrough bleeding, vaginal candidiasis, uterine pain, UTIs, local irritation, fluid retention, mastodynia, nausea, headache, migraine, dizziness. |
| How Supplied |
|
Ring—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
